Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $19.40

Theravance Biopharma, Inc. (NASDAQ:TBPH) has been assigned an average rating of “Hold” from the eight ratings firms that are covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $19.40.

A number of equities analysts have recently weighed in on the company. HC Wainwright cut Theravance Biopharma from a “buy” rating to a “neutral” rating and increased their price target for the stock from $15.00 to $17.00 in a report on Tuesday, July 7th. Wall Street Zen lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings upgraded shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, August 17th. JonesTrading cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, June 29th. Finally, BTIG Research downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Monday, June 29th.

Insider Buying and Selling at Theravance Biopharma

In other news, major shareholder Eli Samaha sold 273,871 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $17.23, for a total transaction of $4,718,797.33. Following the completion of the transaction, the insider directly owned 9,237,279 shares in the company, valued at $159,158,317.17. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction on Monday, June 15th. The shares were sold at an average price of $16.39, for a total value of $218,216.46. Following the completion of the sale, the senior vice president directly owned 232,457 shares of the company’s stock, valued at $3,809,970.23. The trade was a 5.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 350,011 shares of company stock valued at $6,008,309. Company insiders own 7.65% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

Several institutional investors have recently bought and sold shares of the company. Quarry LP purchased a new stake in Theravance Biopharma during the 3rd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd raised its stake in shares of Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 1,411 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 781 shares during the period. CIBC Private Wealth Group LLC boosted its holdings in Theravance Biopharma by 20,269.6% in the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 4,662 shares during the period. Finally, AQR Capital Management LLC purchased a new position in Theravance Biopharma in the first quarter valued at $101,000. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Trading Up 0.1%

Theravance Biopharma stock opened at $17.08 on Friday. The company has a 50-day moving average price of $16.96 and a 200 day moving average price of $16.54. Theravance Biopharma has a 12-month low of $13.08 and a 12-month high of $21.03. The stock has a market cap of $886.79 million, a P/E ratio of 16.91 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.18). The firm had revenue of $20.73 million during the quarter, compared to analysts’ expectations of $22.49 million. Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. As a group, analysts forecast that Theravance Biopharma will post 1.56 EPS for the current year.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.